# Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer

> **NCT00268346** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 58 (actual)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** ZD1839

## Key facts

- **NCT ID:** NCT00268346
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2011-01
- **Final completion:** 2011-08
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2016-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00268346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00268346, "Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00268346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*